Ovid Therapeutics
OVID
82 hedge funds and large institutions have $14.5M invested in Ovid Therapeutics in 2025 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 20 increasing their positions, 28 reducing their positions, and 9 closing their positions.
0% more funds holding
Funds holding: 82 → 82 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 9
1.71% less ownership
Funds ownership: 66.99% → 65.28% (-1.7%)
29% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 28
67% less capital invested
Capital invested by funds: $44.4M → $14.5M (-$29.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
+$758K |
| 2 |
Renaissance Technologies
New York
|
+$563K |
| 3 |
AAA
Affinity Asset Advisors
New York
|
+$410K |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$302K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$222K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SL
Siren LLC
Greenwich,
Connecticut
|
-$2.66M |
| 2 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$881K |
| 3 |
MAP
Madison Avenue Partners
New York
|
-$773K |
| 4 |
MCM
Monimus Capital Management
Woodbridge,
New Jersey
|
-$129K |
| 5 |
JP Morgan Chase
New York
|
-$129K |
OVID Hedge Fund Activity: Q1 2025 in Review
82 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q1 2025, worth a combined $14.5M — down 67% from $44.4M a quarter earlier.
Fund positioning in OVID was balanced in Q1 2025: 9 funds opened new positions, 9 closed out, 20 added to existing stakes and 28 trimmed.
The largest buyer was Sio Capital Management, adding an estimated $758K. The largest seller was Siren LLC, exiting entirely with an estimated $2.66M sold.
- 82 institutional investors held Ovid Therapeutics (OVID) as of Q1 2025, unchanged from Q4 2024.
- Funds reported $14.5M of Ovid Therapeutics stock for Q1 2025, down 67% quarter-over-quarter.
- 9 funds opened new Ovid Therapeutics positions in Q1 2025 and 9 closed out, a net change of 0 holders.
- The largest Ovid Therapeutics buyer in Q1 2025 was Sio Capital Management, an estimated $758K added.
- The largest Ovid Therapeutics seller in Q1 2025 was Siren LLC, an estimated $2.66M sold.
Based on aggregated 13F filings for Q1 2025.